SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pui CH, Robison L, Look AT. Acute lymphoblastic leukemia. Lancet. 2008; 354: 166-178.
  • 2
    Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006; 56: 106-130.
  • 3
    Wartenberg D, Groves FD, Adelman AS. Acute lymphoblastic leukemia: epidemiology and etiology. In: EsteyEH, FaderlS, KantarjianH, eds. Acute Leukemias. 1st ed. Berlin, Germany: Springer; 2008: 77-93.
  • 4
    Kinlen LJ. Infections and immune factors in cancer: the role of epidemiology. Oncogene. 2004; 23: 6341-6348.
  • 5
    Greaves M. Infection, immune responses and aetiology of childhood leukaemia. Nat Rev Cancer. 2006; 6: 193-203.
  • 6
    Healy J, Belanger H, Heaulieu P, et al. Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood. 2007; 109: 683-692.
  • 7
    de Jonge R, Tissing WJE, Hooijberg JH, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood. 2009; 113: 2284-2289.
  • 8
    SwerdlowSH, CampoE, HarrisNL, et al, eds. IARC WHO Classification of Haematopoietic and Lymphoid Tissues, vol 2. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
  • 9
    Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia. Cancer and Leukemia Group B study 8364. Blood. 1999; 93: 3931-3939.
  • 10
    Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998; 16: 3768-3773.
  • 11
    Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009; 46: 100-106.
  • 12
    Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 6306-6315.
  • 13
    Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998; 91: 3995-4019.
  • 14
    Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005; 105: 3434-3441.
  • 15
    Pui CH, Williams WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166-178.
  • 16
    Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109: 3189-3197.
  • 17
    Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 1337-1354.
  • 18
    Faderl S, Albitar M. Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 1267-1288.
  • 19
    Schnapp LM. Another notch on the belt. Blood. 2009; 113: 1615-1616.
  • 20
    Joshi I, Minter LM, Telfer J, et al. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood. 2009; 113: 1689-1698.
  • 21
    Wolfraim LA, Fernandez TM, Mamura M, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med. 2004; 351: 528-530.
  • 22
    Garcia-Manero G, Yang H, Kuang SQ, et al. Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009; 46: 24-32.
  • 23
    Roman-Gomez J, Jimenez-Velasco A, Barrios M, et al. Poor prognosis in acute lymphocytic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma. 2007; 48: 1269-1282.
  • 24
    Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009; 27: 1316-1322.
  • 25
    Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13: 1634-1637.
  • 26
    Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood. 2004; 104: 923-932.
  • 27
    Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446: 758-764.
  • 28
    Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004; 103: 1043-1049.
  • 29
    Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351: 533-542.
  • 30
    Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360: 470-480.
  • 31
    Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2003; 15: 741-756.
  • 32
    Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429: 464-468.
  • 33
    Belkow VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999; 93: 1643-1650.
  • 34
    Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL-AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000; 96: 1094-1099.
  • 35
    Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of ara-C-metabolizing enzymes explains ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003; 101: 1270-1276.
  • 36
    Rocha JCC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005; 105: 4752-4758.
  • 37
    Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001; 1: 99-108.
  • 38
    Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemias to asparaginase. J Clin Invest. 2007; 117: 1049-1057.
  • 39
    Hoelzer D, Thiel H, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988; 71: 123-131.
  • 40
    Kantarjian HM, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
  • 41
    Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the International ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106: 3760-3767.
  • 42
    Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the International ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006; 108: 465-472.
  • 43
    Le Q-H, Thomas X, Ecochard R, et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol. 2006; 77: 471-479.
  • 44
    Asnafi V, Buzyn A, Thomas X, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005; 105: 3072-3078.
  • 45
    Baldus CD, Martus P, Burmeister T, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007; 25: 3739-3745.
  • 46
    Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006; 107: 1116-1123.
  • 47
    Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007; 92: 612-618.
  • 48
    Larson RA, Dodge RK, Burns CP, et al. A 5-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995; 85: 2025-2037.
  • 49
    Goekbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46: 64-75.
  • 50
    Larson RA, Yu D, Sanford BL, Stock W. Recent clinical trials in acute lymphoblastic leukemia by the Cancer and Leukemia Group B. In: EsteyEH, FaderlS, KantarjianH, eds. Acute Leukemias. 1st ed. Berlin, Germany: Springer; 2008: 137-144.
  • 51
    Thomas X, Fiere D. Conventional therapy in adult acute lymphoblastic leukemia: review of the LALA program. In: EsteyEH, FaderlS, KantarjianH, eds. Acute Leukemias. 1st ed. Berlin, Germany: Springer; 2008: 144-159.
  • 52
    Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20: 2464-2471.
  • 53
    Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with 4 other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002; 16: 1259-1266.
  • 54
    Hallbook H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2002; 118: 748-754.
  • 55
    Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk acute lymphoblastic leukemia. J Clin Oncol. 2005; 28: 7161-7167.
  • 56
    Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003; 55: 1293-1302.
  • 57
    Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007; 109: 4164-4167.
  • 58
    Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007; 109: 2744-2750.
  • 59
    Maury S, Huguet F, Pigneux A, et al. Prognostic significance of CD20 expression in adult B-cell precursor acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 832a. Abstract 2829.
  • 60
    Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr. 2008; 20: 17-22.
  • 61
    Thomas DA, Kantarjian H, Faderl S, et al. Update of the modified hyper-CVAD regimen with or without rituximab as frontline therapy of adults with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 831a. Abstract 2824.
  • 62
    Durrant IJ, Richards SM, Prentice HG, et al. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 1327-1352.
  • 63
    Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99: 863-871.
  • 64
    Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113: 4153-4162.
  • 65
    Goekbuget N, Arnold R, Bohme A, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL Study 07/2003 [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 11a. Abstract 12.
  • 66
    O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasoe regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008; 113: 2097-2101.
  • 67
    Goekbuget N, Leguay T, Hunault M, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112: 118. Abstract 304.
  • 68
    Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007; 13: 1083-1094.
  • 69
    Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994; 12: 2580-2587.
  • 70
    Vey N, Blaise D, Stoppa AM, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1994; 14: 383-388.
  • 71
    Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111: 1827-1833.
  • 72
    Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22: 4075-4086.
  • 73
    Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med. 1991; 115: 13-18.
  • 74
    Goldstone AH. Transplants in adult ALL—? Allo for everyone. Biol Blood Marrow Transplant. 2009; 15: 7-10.
  • 75
    Larson RA. Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2009; 15: 11-16.
  • 76
    Bishop MR, Logan BR, Gandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 41: 635-642.
  • 77
    Marks DI, Aversa F, Lazarus HM. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the 3 major options. Bone Marrow Transplant. 2006; 38: 467-475.
  • 78
    Massenkeil G, Nagy M, Neuburger S, et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant. 2005; 36: 683-689.
  • 79
    Bachanova V, Verneris MR, Defor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009; 113: 2902-2905.
  • 80
    Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112: 1646-1654.
  • 81
    Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780.
  • 82
    Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALL XII/E2993) trials. Pediatr Blood Cancer. 2007; 48: 254-261.
  • 83
    Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 Study. J Clin Oncol. 2009; 27: 911-918.
  • 84
    DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 587. Abstract 181a.
  • 85
    Haiat S, Vekhoff A, Marzac C, et al. Improved outcome of adult acute lymphoblastic leukemia treated with a pediatric protocol: results of pilot study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 2822. Abstract 830a.
  • 86
    Fielding AK, Goldstone AH. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2008; 41: 447-453.
  • 87
    Thomas DA, Kantarjian HM, Ravandi F, et al. Long-term follow-up after frontline therapy with the hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 9. Abstract 10a.
  • 88
    Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006; 20: 460-466.
  • 89
    de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007; 109: 1408-1413.
  • 90
    Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108: 1469-1477.
  • 91
    Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B. Blood. 2007; 109: 3676-3678.
  • 92
    Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 2309-2315.
  • 93
    Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2007; 354: 2542-2551.
  • 94
    Foa R, Vignetti M, Vitale A, et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205 [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 7. Abstract 10a.
  • 95
    Ravandi F, Thomas D, Kantarjian H, et al. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110: 2814. Abstract 828a.
  • 96
    Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109: 944-950.
  • 97
    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
  • 98
    Kebriaei P, Champlin R. The role of allogeneic stem cell transplantation in the therapy of adult acute lymphoblastic leukemia (ALL). In: EsteyEH, FaderlS, KantarjianH, eds. Acute Leukemias. 1st ed. Berlin, Germany: Springer; 2008: 215-228.
  • 99
    Lamanna N, von Hassel M, Weiss M. Relapsed acute lymphoblastic leukemia. In: EsteyEH, FaderlS, KantarjianH, eds. Acute Leukemias. 1st ed. Berlin, Germany: Springer; 2008: 275-279.
  • 100
    Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat Rev Drug Discov. 2007; 6: 149-165.
  • 101
    Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23: 3376-3382.
  • 102
    DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007; 109: 5136-5142.
  • 103
    Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006; 24: 1917-1923.